{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:43:29Z","timestamp":1790423009656,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["61803151"],"award-info":[{"award-number":["61803151"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Scientific Foundation of Hunan Province","award":["2018JJ3570"],"award-info":[{"award-number":["2018JJ3570"]}]},{"name":"Natural Scientific Foundation of Hunan Province","award":["2018JJ2461"],"award-info":[{"award-number":["2018JJ2461"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The outbreak of a novel febrile respiratory disease called COVID-19, caused by a newfound coronavirus SARS-CoV-2, has brought a worldwide attention. Prioritizing approved drugs is critical for quick clinical trials against COVID-19. In this study, we first manually curated three Virus-Drug Association (VDA) datasets. By incorporating VDAs with the similarity between drugs and that between viruses, we constructed a heterogeneous Virus-Drug network. A novel Random Walk with Restart method (VDA-RWR) was then developed to identify possible VDAs related to SARS-CoV-2. We compared VDA-RWR with three state-of-the-art association prediction models based on fivefold cross-validations (CVs) on viruses, drugs and virus-drug associations on three datasets. VDA-RWR obtained the best AUCs for the three fivefold CVs, significantly outperforming other methods. We found two small molecules coming together on the three datasets, that is, remdesivir and ribavirin. These two chemical agents have higher molecular binding energies of \u2212\u00a07.0\u00a0kcal\/mol and \u2212\u00a06.59 kcal\/mol with the domain bound structure of the human receptor angiotensin converting enzyme 2 (ACE2) and the SARS-CoV-2 spike protein, respectively. Interestingly, for the first time, experimental results suggested that navitoclax could be potentially applied to stop SARS-CoV-2 and remains to further validation.<\/jats:p>","DOI":"10.1038\/s41598-021-83737-5","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T16:47:41Z","timestamp":1616086061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Prioritizing antiviral drugs against SARS-CoV-2 by integrating viral complete genome sequences and drug chemical structures"],"prefix":"10.1038","volume":"11","author":[{"given":"Lihong","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongfei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuxing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,18]]},"reference":[{"key":"83737_CR1","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ijid.2020.01.009","volume":"91","author":"DS Hui","year":"2020","unstructured":"Hui, D. S. et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health: The latest 2019 novel coronavirus outbreak in Wuhan, China. Int. J. Infect. Dis. 91, 264\u2013266 (2020).","journal-title":"Int. J. Infect. Dis."},{"key":"83737_CR2","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet 395, 565\u2013574 (2020).","journal-title":"The Lancet"},{"key":"83737_CR3","unstructured":"WHO. Coronavirus disease 2019 (COVID-19) Situation Report- COVID-19 Weekly Epidemiological Update. (2020). Organ. WHO (2020). (https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/situation-reports\/20201020weekly-epi-update-10.pdf. Accessed 20 Oct 2020."},{"key":"83737_CR4","unstructured":"Organization, W. H. US $675 Million Needed for New Coronavirus Preparedness and Response Global Plan [Internet]. Geneva: World Health Organization; 2020 [cited 2020 Feb 5]. (2020)."},{"key":"83737_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 395, 497\u2013506 (2020).","journal-title":"The Lancet"},{"key":"83737_CR6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269\u2013271 (2020).","journal-title":"Cell Res."},{"key":"83737_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5582\/bst.2020.01020","volume":"14","author":"H Lu","year":"2020","unstructured":"Lu, H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci. Trends 14, 69\u201371 (2020).","journal-title":"Biosci. Trends"},{"key":"83737_CR8","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202001.0358.v3","author":"H Chen","year":"2020","unstructured":"Chen, H. & Du, Q. Potential natural compounds for preventing SARS-CoV-2 (2019-nCoV) infection. Preprints https:\/\/doi.org\/10.20944\/preprints202001.0358.v3 (2020).","journal-title":"Preprints"},{"key":"83737_CR9","doi-asserted-by":"publisher","DOI":"10.1101\/2020.01.28.922922","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. Therapeutic drugs targeting 2019-nCoV main protease by high-throughput screening. bioRxiv https:\/\/doi.org\/10.1101\/2020.01.28.922922 (2020).","journal-title":"bioRxiv"},{"key":"83737_CR10","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202002.0071.v1","author":"S Kumar","year":"2020","unstructured":"Kumar, S. Drug and vaccine design against novel coronavirus (2019-nCoV) spike protein through computational approach. Preprints https:\/\/doi.org\/10.20944\/preprints202002.0071.v1 (2020).","journal-title":"Preprints"},{"key":"83737_CR11","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202002.0061.v1","author":"H Zhang","year":"2020","unstructured":"Zhang, H. et al. Deep learning based drug screening for novel coronavirus 2019-nCov. Interdiscip. Sci. Comput. Life Sci. https:\/\/doi.org\/10.20944\/preprints202002.0061.v1 (2020).","journal-title":"Interdiscip. Sci. Comput. Life Sci."},{"key":"83737_CR12","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.csbj.2020.03.025","volume":"18","author":"BR Beck","year":"2020","unstructured":"Beck, B. R., Shin, B., Choi, Y., Park, S. & Kang, K. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Comput. Struct. Biotechnol. J. 18, 784\u2013790 (2020).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"83737_CR13","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"83737_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-016-1111-6","volume":"15","author":"Y-A Huang","year":"2017","unstructured":"Huang, Y.-A. et al. Prediction of microbe\u2013disease association from the integration of neighbor and graph with collaborative recommendation model. J. Transl. Med. 15, 1\u201311 (2017).","journal-title":"J. Transl. Med."},{"key":"83737_CR15","doi-asserted-by":"publisher","first-page":"45584","DOI":"10.18632\/oncotarget.10052","volume":"7","author":"J Li","year":"2016","unstructured":"Li, J. et al. Network-based identification of microRNAs as potential pharmacogenomic biomarkers for anticancer drugs. Oncotarget 7, 45584\u201345596 (2016).","journal-title":"Oncotarget"},{"key":"83737_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-016-0028-x","volume":"7","author":"F Wang","year":"2017","unstructured":"Wang, F. et al. LRLSHMDA: Laplacian regularized least squares for human microbe\u2013disease association prediction. Sci. Rep. 7, 1\u201311 (2017).","journal-title":"Sci. Rep."},{"key":"83737_CR17","first-page":"845","volume":"1","author":"BJ McConkey","year":"2002","unstructured":"McConkey, B. J., Sobolev, V. & Edelman, M. The performance of current methods in ligand\u2013protein docking. Curr. Sci. 1, 845\u2013856 (2002).","journal-title":"Curr. Sci."},{"key":"83737_CR18","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2174\/157340911795677602","volume":"7","author":"X-Y Meng","year":"2011","unstructured":"Meng, X.-Y., Zhang, H.-X., Mezei, M. & Cui, M. Molecular docking: A powerful approach for structure-based drug discovery. Curr. Comput. Aided Drug Des. 7, 146\u2013157 (2011).","journal-title":"Curr. Comput. Aided Drug Des."},{"key":"83737_CR19","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris, G. M. et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 30, 2785\u20132791 (2009).","journal-title":"J. Comput. Chem."},{"key":"83737_CR20","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3390\/v11040326","volume":"11","author":"EP Tchesnokov","year":"2019","unstructured":"Tchesnokov, E. P., Feng, J. Y., Porter, D. P. & G\u00f6tte, M. Mechanism of inhibition of ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses 11, 326 (2019).","journal-title":"Viruses"},{"key":"83737_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-13940-6","volume":"11","author":"TP Sheahan","year":"2020","unstructured":"Sheahan, T. P. et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun. 11, 1\u201314 (2020).","journal-title":"Nat. Commun."},{"key":"83737_CR22","doi-asserted-by":"publisher","first-page":"104541","DOI":"10.1016\/j.antiviral.2019.104541","volume":"169","author":"AJ Brown","year":"2019","unstructured":"Brown, A. J. et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res. 169, 104541 (2019).","journal-title":"Antiviral Res."},{"key":"83737_CR23","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/cbic.202000047","volume":"21","author":"JS Morse","year":"2020","unstructured":"Morse, J. S., Lalonde, T., Xu, S. & Liu, W. R. Learning from the past: Possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. ChemBioChem 21, 730\u2013738 (2020).","journal-title":"ChemBioChem"},{"key":"83737_CR24","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1001\/jama.2020.0757","volume":"323","author":"CI Paules","year":"2020","unstructured":"Paules, C. I., Marston, H. D. & Fauci, A. S. Coronavirus infections: more than just the common cold. JAMA 323, 707\u2013708 (2020).","journal-title":"JAMA"},{"key":"83737_CR25","doi-asserted-by":"publisher","DOI":"10.26434\/chemrxiv.11831103","author":"YW Chen","year":"2020","unstructured":"Chen, Y. W., Yiu, C.-P. & Wong, K.-Y. Prediction of the 2019-nCoV 3C-like protease (3CLpro) structure: Virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. ChemRxiv https:\/\/doi.org\/10.26434\/chemrxiv.11831103 (2020).","journal-title":"ChemRxiv"},{"key":"83737_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0140-6736(20)30305-6","volume":"395","author":"A Zumla","year":"2020","unstructured":"Zumla, A., Hui, D. S., Azhar, E. I., Memish, Z. A. & Maeurer, M. Reducing mortality from 2019-nCoV: Host-directed therapies should be an option. The Lancet 395, 35\u201336 (2020).","journal-title":"The Lancet"},{"key":"83737_CR27","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0140-6736(20)30300-7","volume":"395","author":"F-S Wang","year":"2020","unstructured":"Wang, F.-S. & Zhang, C. What to do next to control the 2019-nCoV epidemic?. The Lancet 395, 391\u2013393 (2020).","journal-title":"The Lancet"},{"key":"83737_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1080\/01652176.2020.1727993","volume":"40","author":"YS Malik","year":"2020","unstructured":"Malik, Y. S. et al. Emerging novel coronavirus (2019-nCoV)\u2014current scenario, evolutionary perspective based on genome analysis and recent developments. Vet. Q. 40, 68\u201376 (2020).","journal-title":"Vet. Q."},{"key":"83737_CR29","unstructured":"FDA. FDA\u2019s approval of Veklury (remdesivir) for the treatment of COVID-19\u2014The Science of Safety and Effectiveness. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fdas-approval-veklury-remdesivir-treatment-covid-19-science-safety-and-effectiveness, October 22, 2020. Accessed 24 Oct 2020."},{"key":"83737_CR30","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s12250-020-00203-8","volume":"35","author":"Z Zhang","year":"2020","unstructured":"Zhang, Z. et al. Clinical features and treatment of 2019-nCov pneumonia patients in Wuhan: Report of a couple cases. Virol. Sin. 35, 330\u2013336 (2020).","journal-title":"Virol. Sin."},{"key":"83737_CR31","unstructured":"Schrodinger, L. The PyMOL molecular graphics system. Version 1, (2010)."},{"key":"83737_CR32","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1126\/science.1176062","volume":"324","author":"C Fraser","year":"2009","unstructured":"Fraser, C. et al. Pandemic potential of a strain of influenza A (H1N1): EARLY FINDINGS. Science 324, 1557\u20131561 (2009).","journal-title":"Science"},{"key":"83737_CR33","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S0140-6736(97)11212-0","volume":"351","author":"EC Claas","year":"1998","unstructured":"Claas, E. C. et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. The Lancet 351, 472\u2013477 (1998).","journal-title":"The Lancet"},{"key":"83737_CR34","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1304459","volume":"368","author":"R Gao","year":"2013","unstructured":"Gao, R. et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N. Engl. J. Med. 368, 1888\u20131897 (2013).","journal-title":"N. Engl. J. Med."},{"key":"83737_CR35","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried, M. W. et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975\u2013982 (2002).","journal-title":"N. Engl. J. Med."},{"key":"83737_CR36","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/337615a0","volume":"337","author":"MA Navia","year":"1989","unstructured":"Navia, M. A. et al. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 337, 615\u2013620 (1989).","journal-title":"Nature"},{"key":"83737_CR37","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1128\/JVI.73.3.2343-2349.1999","volume":"73","author":"A M\u00f6rner","year":"1999","unstructured":"M\u00f6rner, A. et al. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J. Virol. 73, 2343\u20132349 (1999).","journal-title":"J. Virol."},{"key":"83737_CR38","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1099\/0022-1317-81-8-1927","volume":"81","author":"PL Young","year":"2000","unstructured":"Young, P. L., Halpin, K., Mackenzie, J. S. & Field, H. E. Isolation of hendra virus from pteropid bats: A natural reservoir of Hendra virus. J. Gen. Virol. 81, 1927 (2000).","journal-title":"J. Gen. Virol."},{"key":"83737_CR39","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/978-3-642-74980-3_6","volume-title":"Cytomegaloviruses","author":"MS Chee","year":"1990","unstructured":"Chee, M. S. et al. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. In Cytomegaloviruses (ed. McDougall, J. K.) 125\u2013169 (Springer, New York, 1990)."},{"key":"83737_CR40","doi-asserted-by":"publisher","first-page":"7790","DOI":"10.1128\/JVI.01244-13","volume":"87","author":"RJ de Groot","year":"2013","unstructured":"de Groot, R. J. et al. Commentary: Middle east respiratory syndrome coronavirus (MERS-CoV): Announcement of the coronavirus study group. J. Virol. 87, 7790\u20137792 (2013).","journal-title":"J. Virol."},{"key":"83737_CR41","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S1473-3099(18)30292-5","volume":"18","author":"NI Mazur","year":"2018","unstructured":"Mazur, N. I. et al. The respiratory syncytial virus vaccine landscape: Lessons from the graveyard and promising candidates. Lancet Infect. Dis. 18, 295\u2013311 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"83737_CR42","doi-asserted-by":"publisher","first-page":"8455","DOI":"10.1073\/pnas.0400576101","volume":"101","author":"BJ Bosch","year":"2004","unstructured":"Bosch, B. J. et al. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc. Natl. Acad. Sci. 101, 8455\u20138460 (2004).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"83737_CR43","doi-asserted-by":"publisher","first-page":"D9","DOI":"10.1093\/nar\/gkz899","volume":"48","author":"EW Sayers","year":"2020","unstructured":"Sayers, E. W. et al. Database resources of the national center for biotechnology information. Nucleic Acids Res. 48, D9 (2020).","journal-title":"Nucleic Acids Res."},{"key":"83737_CR44","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1093\/bib\/bbx108","volume":"20","author":"K Katoh","year":"2019","unstructured":"Katoh, K., Rozewicki, J. & Yamada, K. D. MAFFT online service: Multiple sequence alignment, interactive sequence choice and visualization. Brief. Bioinform. 20, 1160\u20131166 (2019).","journal-title":"Brief. Bioinform."},{"key":"83737_CR45","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2018","unstructured":"Wishart, D. S. et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 46, D1074\u2013D1082 (2018).","journal-title":"Nucleic Acids Res."},{"key":"83737_CR46","unstructured":"Canese, K. & Weis, S. PubMed: the bibliographic database. in The NCBI Handbook [Internet]. 2nd edition (National Center for Biotechnology Information (US), 2013)."},{"key":"83737_CR47","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1021\/ci100050t","volume":"50","author":"D Rogers","year":"2010","unstructured":"Rogers, D. & Hahn, M. Extended-connectivity fingerprints. J. Chem. Inf. Model. 50, 742\u2013754 (2010).","journal-title":"J. Chem. Inf. Model."},{"key":"83737_CR48","unstructured":"Landrum, G., et al. RDKit: Open-Source Cheminformatics Software. (2016)."},{"key":"83737_CR49","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ijid.2020.02.018","volume":"93","author":"PI Andersen","year":"2020","unstructured":"Andersen, P. I. et al. Discovery and development of safe-in-man broad-spectrum antiviral agents. Int. J. Infect. Dis. 93, 268\u2013276 (2020).","journal-title":"Int. J. Infect. Dis."},{"key":"83737_CR50","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/bioinformatics\/bty637","volume":"35","author":"A Valdeolivas","year":"2019","unstructured":"Valdeolivas, A. et al. Random walk with restart on multiplex and heterogeneous biological networks. Bioinformatics 35, 497\u2013505 (2019).","journal-title":"Bioinformatics"},{"key":"83737_CR51","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"HM Berman","year":"2000","unstructured":"Berman, H. M. et al. The protein data bank. Nucleic Acids Res. 28, 235\u2013242 (2000).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83737-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83737-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83737-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T05:22:10Z","timestamp":1670044930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83737-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,18]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["83737"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-83737-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,18]]},"assertion":[{"value":"18 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors Geng Tian and Jialiang Yang were employed by the company Geneis (Beijing) Co. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6248"}}